PMID- 18345719
OWN - NLM
STAT- MEDLINE
DCOM- 20080808
LR  - 20211203
IS  - 1174-5878 (Print)
IS  - 1174-5878 (Linking)
VI  - 10
IP  - 2
DP  - 2008
TI  - Emerging chemotherapeutic strategies and the role of treatment stratification in 
      Ewing sarcoma.
PG  - 93-105
AB  - The Ewing sarcoma family of tumors (ESFT) is one of the most common groups of 
      malignancies arising in children, adolescents, and young adults up to 
      approximately 25 years of age. It comprises Ewing sarcoma arising from bone and 
      extraosseous Ewing sarcoma arising from soft tissues (which includes peripheral 
      neuroectodermal tumors and Askin tumor arising from the chest wall). Ewing 
      sarcoma is treated successfully in many cases by a combination of chemotherapy, 
      surgery, and radiotherapy. A number of prognostic factors have been identified 
      that can be used to stratify patients according to the risk of relapse, allowing 
      optimization of treatment. These can be categorized as tumor-related factors 
      (presence of metastases, tumor site, volume, lactic dehydrogenase level, 
      chromosomal translocation type, presence of fusion transcripts in blood and bone 
      marrow), treatment-related factors (local therapy, histologic response to 
      chemotherapy, radiologic response to chemotherapy, chemotherapy regimen), and 
      patient-related factors (gender, age). Newer chemotherapeutic agents are 
      currently being investigated, and there is now increasing interest in the 
      identification of molecular targets in ESFT that could be exploited 
      therapeutically, which include the mammalian target of rapamycin (mTOR) and 
      insulin growth factor-1 (IGF-1) receptor pathways.
FAU - Seddon, Beatrice M
AU  - Seddon BM
AD  - London Bone and Soft Tissue Tumor Service, University College Hospital, London, 
      UK. beatrice.seddon@uclh.nhs.uk
FAU - Whelan, Jeremy S
AU  - Whelan JS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Age Factors
MH  - Antineoplastic Protocols
MH  - *Bone Neoplasms/drug therapy/radiotherapy/surgery
MH  - Combined Modality Therapy
MH  - Humans
MH  - Pediatrics
MH  - Prognosis
MH  - Protein Kinases/physiology
MH  - Receptor, IGF Type 1/physiology
MH  - *Sarcoma, Ewing/drug therapy/radiotherapy/surgery
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases
RF  - 126
EDAT- 2008/03/19 09:00
MHDA- 2008/08/09 09:00
CRDT- 2008/03/19 09:00
PHST- 2008/03/19 09:00 [pubmed]
PHST- 2008/08/09 09:00 [medline]
PHST- 2008/03/19 09:00 [entrez]
AID - 1024 [pii]
AID - 10.2165/00148581-200810020-00004 [doi]
PST - ppublish
SO  - Paediatr Drugs. 2008;10(2):93-105. doi: 10.2165/00148581-200810020-00004.